Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
VUMC, Nashville, Tennessee, United States
University of Iowa, Iowa City, Iowa, United States
Hospital das Clinicas, Sao Paulo, SP, Brazil
Chonbuk National University Hospital, Chonbuk, Korea, Republic of
ErasmusMC, Rotterdam, Netherlands
Columbia University Medical Center, New York, New York, United States
Chonbuk National University Hospital, Chonbuk, Korea, Republic of
VA New York Harbor Healthcare System, New York, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.